首页> 外文期刊>中华医学杂志(英文版) >Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion
【24h】

Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion

机译:阿托伐他汀和普罗布考联合治疗对边缘性冠脉病变患者血浆胱抑素C水平和冠脉病变严重程度的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background The plasma cystatin C concentration (PcyC) has been demonstrated to have prognostic value in acute coronary syndrome,but the study of PcyC in patients with borderline coronary lesions is limited.Moreover,the effects of atorvastatin and probucol on PcyC and the severity of coronary lesions are unknown.This study was to evaluate the effects of the combination of atorvastatin and probucol on PcyC and severity of coronary lesion in patients with borderline coronary lesions.Methods One hundred and thirty consecutive patients with borderline coronary lesions (40% to 60% isolated single stenosis assessed by quantitative coronary angiography) were enrolled into the borderline coronary lesion (BCL) group,and one hundred and thirty-six subjects without coronary lesions comprised the controls (CTR).The subjects in the BCL group were randomized into routine treatment (RTT,n=60),and combined treatment with atorvastatin 20 mg plus probucol 1.0 g daily added to routine medication (CBT,n=70),both groups were treated for 6 months continuously.The levels of PcyC,high-sensitive C-reactive protein (hs-CRP),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol(HDL-C),and triglycerides (TG) were determined.One hundred and four subjects in the BCL group were rechecked by coronary angiography.Results PcyC levels were significantly higher in the BCL group than in the CTR group;(2003.26±825.73) ng/ml vs.(1897.83±664.46) ng/ml (P<0.01).Compared with patients in the RTT group,the levels of PcyC,TC,LDL-C,TG and hs-CRP were significantly lower in the CBT group (P<0.05).Moreover,there was a trend towards a slight decrease in the RTT patients,(54.38±10.67)% vs.(50.29±9.89)% (P >0.05),and a significant decrease in the CBT patients,(53.65±9.48%) vs.(40.38±12.93)% (P<0.05),in the mean percent stenosis of borderline coronary lesions before and after six months of treatment.Conclusions Cystatin C played an important role in the development of coronary artery disease,and was associated with the severity of coronary lesions.The combination of atorvastatin and probucol decreased PcyC levels,and could be the treatment of choice.
机译:背景血浆半胱氨酸蛋白酶抑制剂C(PcyC)已被证明对急性冠状动脉综合征具有预后价值,但对边缘性冠脉病变患者的PcyC研究仍然有限。此外,阿托伐他汀和普罗布考对PcyC的影响以及冠状动脉的严重程度本研究旨在评估阿托伐他汀和普罗布考联合使用对边缘性冠状动脉病变患者的PcyC和冠状动脉病变程度的影响。方法连续130例边缘性冠状动脉病变患者(40%至60%被隔离)将通过定量冠状动脉造影评估的单次狭窄入选为边缘性冠状动脉病变(BCL)组,并将136例无冠状动脉病变的受试者作为对照(CTR).BCL组中的受试者被随机分为常规治疗( RTT,n = 60),并在常规药物中每天加用阿托伐他汀20 mg加普罗布考1.0 g联合治疗(CBT,n = 70) ),两组均连续治疗6个月.PcyC,高敏C反应蛋白(hs-CRP),总胆固醇(TC),低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白的水平测定了胆固醇(HDL-C)和甘油三酸酯(TG)。BCL组的104名受试者接受了冠状动脉造影检查。结果BCL组的PcyC水平明显高于CTR组;(2003.26±825.73) ng / ml与(1897.83±664.46)ng / ml(P <0.01)。与RTT组患者相比,CBT中PcyC,TC,LDL-C,TG和hs-CRP的水平明显降低组(P <0.05)。RTT患者有轻度下降的趋势,分别为(54.38±10.67)%和(50.29±9.89)%(P> 0.05),而CBT患者有明显下降的趋势。 ,在治疗六个月前后,边缘性冠状动脉病变的平均狭窄百分比为(53.65±9.48%)vs.(40.38±12.93)%(P <0.05)。阿托伐他汀联合普罗布考降低了PcyC水平,可能是治疗的选择。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2012年第14期|2472-2476|共5页
  • 作者单位

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology, Peking University First Hospital,Beijing 100034. China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

    Department of Cardiology. Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号